Clinical Cardiology Alert – February 1, 2020
February 1, 2020
View Issues
-
Stenting Nonculprit Lesions After STEMI: Long-Term Data Support Complete Revascularization
Data from the CvLPRIT trial of complete vs. culprit-only percutaneous coronary intervention in ST-segment elevation myocardial infarction (MI) show a significantly lower rate of major adverse cardiovascular events, all-cause mortality, and lower composite MI in the complete revascularization group at a median follow-up of 5.6 years.
-
Subclinical Atrial Fibrillation Detected By Implanted Loop Recorders: Common, But How Burdensome?
In older patients with risk factors for stroke drawn from the general population, previously undiagnosed and asymptomatic episodes of atrial fibrillation are detected frequently via implantable loop recorder monitoring, allowing for early initiation of anticoagulation therapy.
-
Aggressive Afterload Reduction Does Not Improve Outcomes in Acute Decompensated Heart Failure
The authors of the GALACTIC trial found no benefit from an aggressive vasodilation approach for patients hospitalized with acute decompensated heart failure.
-
The Risk of Endocarditis With Bacteremia
Interrogation of the Danish National Patient Registry revealed bacteremia due to Enterococcus faecalis was most likely to be associated with infective endocarditis; thus, echocardiography is warranted in these patients.
-
Optimal Antithrombic Therapy After PCI for Atrial Fibrillation Patients
In three subgroups of coronary artery disease patients with atrial fibrillation, apixaban plus a P2Y12 inhibitor provided superior safety and similar efficacy outcomes as treatment with warfarin, aspirin, or both for six months.